State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Pfizer Inc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.79, while Pfizer Inc trades at $25.07 (market cap $141.46B). The key difference: Pfizer Inc pays a 6.93% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none, and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| FLRN | PFE | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $30.86 | $28.56 |
52-Week Low | $30.65 | $23.29 |
Market Cap | — | $141.46B |
Volume | — | 29,869,932 |
Enterprise Value | — | $192.12B |
Dividend Yield | — | 6.93% |
Signals from Pluang's Aura AI — not financial advice
FLRN trades at $30.79 with no price movement in the last 24 hours. The technical picture shows a bearish trend with moving averages indicating selling pressure, though oscillators are neutral. Key financial ratios including P/E, P/S, and ROE are unavailable in the current data. Recent corporate actions include three dividend payments of $0.11 each scheduled for mid-2026, suggesting management's commitment to shareholder returns despite the current technical weakness.
The outlook for FLRN appears cautious with bearish technical signals dominating. The stock faces headwinds from the current market environment where inflation concerns are driving investors toward inflation-protected assets. Investment opportunities exist in the consistent dividend payments, but risks include the overall bearish technical setup and potential pressure from rising interest rates that could impact stock valuations broadly.
Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.
Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.
Trailing returns across standard periods
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →